HHS will let compounding pharmacies make six unapproved peptides

Overview

Updated 1 hour ago

Patients who buy peptide injections online for muscle growth, injury healing, and longevity may soon find them at their local pharmacy. Health and Human Services said it will not penalize small compounding pharmacies that produce six peptides never approved by the Food and Drug Administration.

The policy moves production out of a gray market of 'research-use-only' chemicals, where drugs often come from overseas suppliers of unknown quality. It applies only to small 503A compounders — pharmacies that mix drugs to order — not the larger 503B outsourcing facilities. Industry leaders say those small pharmacies cannot meet existing demand.

Why it matters

If it holds, six popular unproven peptides shift from internet gray markets to licensed pharmacies — with a prescription but without FDA safety review.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

Peptides covered by the policy

BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500.

FDA approvals among the six

None of the six peptides has passed FDA drug review.

14 days

Public comment period

Opens after the policy is published October 30.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Robert F. Kennedy Jr.

Secretary of Health and Human Services

Pushed the policy through his office over FDA staff opposition

Joshua Fritzler

President, Olympia and Wesley Pharmaceuticals

Says his company can only compound one of the six peptides

Scott Brunner

CEO, Alliance for Pharmacy Compounding

Welcomed the policy with caveats about supply

Dr. Robert Steinbrook

Director, Public Citizen Health Research Group

Opposes the policy

Organizations Involved

U.S. Department of Health and Human Services (HHS)

Federal Cabinet Department

Posted the enforcement-discretion policy

The federal department that manages Medicare, Medicaid, the FDA, and the CDC.

U.S. Food and Drug Administration

Federal Regulatory Agency

Scientific staff opposed the policy

The federal agency that reviews drugs for safety and effectiveness before they can be sold in the U.S.

Public Citizen

Consumer Advocacy Nonprofit

Opposes the policy

Consumer advocacy nonprofit founded by Ralph Nader that opposes the peptide policy.

Alliance for Pharmacy Compounding

Trade Association

Welcomed the policy

Trade group for compounding pharmacies that welcomed the policy.

Partnership for Safe Medicines

Industry nonprofit

Filed a citizen petition against the policy

Coalition of pharmacy and pharmacist groups that filed a citizen petition against the policy.

Timeline

July 2026 October 2026

4 events Latest: Yesterday

Tap a bar to jump to that date

October 2026
Policy publication and comment period scheduled
Upcoming Policy

HHS plans to publish the final policy, opening a two-week public comment period before it takes effect.
Tomorrow
HHS announces enforcement-discretion policy
Latest Policy

The health department said it will not penalize small 503A compounding pharmacies that make the six unapproved peptides, provided prescriptions and quality checks are in place.
Yesterday
Pharmacy coalition files citizen petition
Legal

Partnership for Safe Medicines urged the FDA to reject its advisory committee's recommendation on the six peptides.
October 2026
July 2026
FDA advisory committee votes for peptide access
Regulatory

The panel backed expanded compounding access to six peptides over the objection of FDA scientific staff.
July 2026

Scenarios

HHS finalizes peptide policy after comment period

Likely Resolves by Dec 15, 2026

Discussed by: Alliance for Pharmacy Compounding; industry observers

HHS reviews comments and publishes a final enforcement-discretion policy in late November or December. Licensed 503A pharmacies begin compounding the six peptides for patients with prescriptions. Supply will be limited at first while pharmacies verify ingredients and ready facilities.

Court or consumer groups block the policy

Possible Resolves by Q1 2027

Discussed by: Public Citizen; Partnership for Safe Medicines

Consumer groups escalate beyond the citizen petition to litigation or congressional pressure. A court finding that the enforcement-discretion approach bypassed proper rulemaking would halt it before pharmacies can ramp up. Public Citizen has already accused Kennedy of acting unilaterally.

Policy stands but supply stays scarce

Likely Resolves by Q2 2027

Discussed by: Joshua Fritzler (Olympia and Wesley Pharmaceuticals)

The policy survives, but only a handful of small compounders produce the peptides. Fritzler predicts most 503A facilities will compound at most one of the six substances. Patients who cannot get a local pharmacy to fill a prescription keep buying 'research-grade' peptides online from overseas suppliers.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

September-October 2012

New England Compounding Center outbreak (2012)

A Massachusetts compounding pharmacy shipped thousands of vials of steroid injections contaminated with fungus. The injections sickened hundreds of patients across 20 states and killed more than 60 people, making it the deadliest drug-safety failure in modern U.S. history.

Then

The company collapsed. Congress passed the Drug Quality and Security Act in 2013, creating the 503A/503B distinction between small compounders and larger outsourcing facilities.

Now

The law tightened federal oversight of compounding, but small 503A pharmacies still answer mostly to state boards. The outbreak remains the reference point for any debate about unapproved compounded drugs.

Why this matters now

The 503A/503B framework the peptide policy relies on was born from this outbreak. Critics warn that expanding access to unapproved compounds revives the safety risks that outbreak exposed.

October 1994

Dietary Supplement Health and Education Act (1994)

Congress passed a law classifying vitamins, herbs, and other supplements as foods rather than drugs, exempting them from FDA premarket approval. Products went straight to shelves as long as manufacturers did not claim to treat disease.

Then

The supplement market grew rapidly with little federal review of ingredients or claims.

Now

Consumers gained wide access to products with thin evidence, and the FDA has struggled to pull unsafe ones from the market.

Why this matters now

Both situations involve popular health products reaching consumers without FDA approval because of enforcement restraint. The peptide policy extends that pattern from oral supplements to prescription injectables.